142 related articles for article (PubMed ID: 18694393)
21. Stem cell models for drug discovery and toxicology studies.
Liu W; Deng Y; Liu Y; Gong W; Deng W
J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
[TBL] [Abstract][Full Text] [Related]
22. iPS cell derived neuronal cells for drug discovery.
Heilker R; Traub S; Reinhardt P; Schöler HR; Sterneckert J
Trends Pharmacol Sci; 2014 Oct; 35(10):510-9. PubMed ID: 25096281
[TBL] [Abstract][Full Text] [Related]
23. Human pluripotent stem cells for disease modelling and drug screening.
Maury Y; Gauthier M; Peschanski M; Martinat C
Bioessays; 2012 Jan; 34(1):61-71. PubMed ID: 22038777
[TBL] [Abstract][Full Text] [Related]
24. High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules.
Andrews PD; Becroft M; Aspegren A; Gilmour J; James MJ; McRae S; Kime R; Allcock RW; Abraham A; Jiang Z; Strehl R; Mountford JC; Milligan G; Houslay MD; Adams DR; Frearson JA
Biochem J; 2010 Nov; 432(1):21-33. PubMed ID: 20854259
[TBL] [Abstract][Full Text] [Related]
25. High-throughput screening: update on practices and success.
Fox S; Farr-Jones S; Sopchak L; Boggs A; Nicely HW; Khoury R; Biros M
J Biomol Screen; 2006 Oct; 11(7):864-9. PubMed ID: 16973922
[TBL] [Abstract][Full Text] [Related]
26. Embryonic stem cells as a novel cell source of cell-based biosensors.
Liu Q; Huang H; Cai H; Xu Y; Li Y; Li R; Wang P
Biosens Bioelectron; 2007 Jan; 22(6):810-5. PubMed ID: 16621504
[TBL] [Abstract][Full Text] [Related]
27. Adapting high-throughput screening methods and assays for biocontainment laboratories.
Rasmussen L; Tigabu B; White EL; Bostwick R; Tower N; Bukreyev A; Rockx B; LeDuc JW; Noah JW
Assay Drug Dev Technol; 2015; 13(1):44-54. PubMed ID: 25710545
[TBL] [Abstract][Full Text] [Related]
28. Human iPS Cell-Derived Patient Tissues and 3D Cell Culture Part 1: Target Identification and Lead Optimization.
Eglen RM; Reisine T
SLAS Technol; 2019 Feb; 24(1):3-17. PubMed ID: 30286296
[TBL] [Abstract][Full Text] [Related]
29. [High throughput pharmacology for drug discovery].
Ozaki H; Imaizumi Y; Oishi K; Kohama K
Nihon Yakurigaku Zasshi; 2001 Sep; 118(3):187-96. PubMed ID: 11577459
[TBL] [Abstract][Full Text] [Related]
30. Unbiased Forward Genetic Screening with Chemical Mutagenesis to Uncover Drug-Target Interactions.
Horn M; Metge F; Denzel MS
Methods Mol Biol; 2019; 1953():23-31. PubMed ID: 30912013
[TBL] [Abstract][Full Text] [Related]
31. G-protein coupled receptor assays: to measure affinity or efficacy that is the question.
Williams C; Sewing A
Comb Chem High Throughput Screen; 2005 Jun; 8(4):285-92. PubMed ID: 16101004
[TBL] [Abstract][Full Text] [Related]
32. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project.
Mandenius CF; Andersson TB; Alves PM; Batzl-Hartmann C; Björquist P; Carrondo MJ; Chesne C; Coecke S; Edsbagge J; Fredriksson JM; Gerlach JC; Heinzle E; Ingelman-Sundberg M; Johansson I; Küppers-Munther B; Müller-Vieira U; Noor F; Zeilinger K
Altern Lab Anim; 2011 May; 39(2):147-71. PubMed ID: 21639679
[TBL] [Abstract][Full Text] [Related]
33. The application of high-throughput screening to novel lead discovery.
Kenny BA; Bushfield M; Parry-Smith DJ; Fogarty S; Treherne JM
Prog Drug Res; 1998; 51():245-69. PubMed ID: 9949864
[TBL] [Abstract][Full Text] [Related]
34. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
Clements M; Millar V; Williams AS; Kalinka S
Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
[TBL] [Abstract][Full Text] [Related]
35. A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules.
Fouda A; Tahsini M; Khodayarian F; Al-Nafisah F; Rafei M
J Vis Exp; 2017 Mar; (121):. PubMed ID: 28362377
[TBL] [Abstract][Full Text] [Related]
36. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
McGivern JV; Ebert AD
Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
[TBL] [Abstract][Full Text] [Related]
37. Interpretation of uniform-well readouts.
Josiah S
Methods Mol Biol; 2009; 486():177-92. PubMed ID: 19347624
[TBL] [Abstract][Full Text] [Related]
38. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
Steel D; Hyllner J; Sartipy P
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
[TBL] [Abstract][Full Text] [Related]
39. Affinity-based screening techniques for enhancing lead discovery.
Comess KM; Schurdak ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
[TBL] [Abstract][Full Text] [Related]
40. Use of primary human cells in high-throughput screens.
Dunne A; Jowett M; Rees S
Methods Mol Biol; 2009; 565():239-57. PubMed ID: 19551366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
